Lupin announces resolution of US FDA warning letter for its Goa & Pithampur facilities
New Delhi: Global pharma major Lupin Limited (Lupin) today spoken that it has received correspondence from the US FDA that it has now addressed the concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore. This is without the satisfactory evaluation of the touching-up deportment taken by the visitor in response to the Warning Letter that was issued on November 6, 2017.
“We are pleased to be informed by the US FDA that we have addressed the concerns through our touching-up deportment related to the November 2017 Warning Letter. We are single-minded to stuff compliant with good manufacturing practices, and to uphold global quality standards and ensuring the quality of our products,” said Nilesh Gupta, Managing Director, Lupin.
Lupin is an innovation-led transnational pharmaceutical visitor headquartered in Mumbai, India. The Visitor develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and wideness the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The post Lupin announces resolution of US FDA warning letter for its Goa & Pithampur facilities appeared first on BioVoiceNews.
